US Food and Drug Administration approves 'Dupixent' for treatment of bronchitis

WASHINGTON, 28th September, 2024 (WAM) -- The US Food and Drug Administration (FDA) has approved French pharmaceutical company Sanofi's Dupixent, an anti-bronchitis drug for smokers.

According to the Washington Post, the drug's approval followed EU and Chinese approval, and was based on two studies that showed that Dupixent significantly reduced the progression of the disease and "improved respiratory function and quality of life" for its users.

Smoking is the leading cause of chronic obstructive pulmonary disease (COPD), in more than 70 per cent of cases in high-income countries, and is the third leading cause of death in the world, according to the World Health Organisation (WHO).

Symptoms include chronic coughing, shortness of breath, excessive mucus production, and difficulty climbing stairs.